Daraxonrasib combined with chemotherapy left tumours undetectable on CT scans in around 8% of participants in an early pancreatic cancer trial, according to BBC News. The study involved 61 people whose recently diagnosed cancer had spread to other parts of the body. Source
Undetectable tumours aren't proof of a cure. Doctors caution that it's unclear how long the treatment might control the disease. Source
What the trial found
The phase I/II trial combined daraxonrasib, a daily pill, with the chemotherapy drugs gemcitabine and nab-paclitaxel, the BBC reports. These results are for the combination, not the pill alone. Source
The BBC reported three overlapping measures of response:
- 90% of patients had tumours stop growing.
- Just over 60% saw their tumours shrink or disappear.
- Around 8%, or roughly one in 12, had tumours become undetectable on CT scans. Source
The trial followed patients for an average of a year and a half. Some did not see their cancer return during that time, but longer studies are needed to establish how long responses last. Source
Dr Sam Godfrey of Cancer Research UK told BBC News: “Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed.” Source
Why the excitement—and what remains unproven
Cancer Research UK called the findings “the biggest leap forward in decades,” according to the BBC. Pancreatic cancer has the lowest survival rate of all common cancers in the UK, the report notes. Source
The BBC describes daraxonrasib as targeting RAS mutations that drive tumour growth in most pancreatic cancers. Godfrey called it a way of “drugging the undruggable.” Source
But a stronger tumour response and longer survival are different outcomes. Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who is involved in the trial, told the BBC that deeper responses and longer disease control “may eventually translate into longer survival.” Source
Comments